Niacin and heart disease prevention: Engraving its tombstone is a mistake

Journal of Clinical Lipidology

Volumn 11, Issue 6, 2017, Pages 1309-1317

  Superko, Harold Robert ^a   Zhao, Xue Qiao ^b   Hodis, Howard N ^c   Guyton, John R ^d  

^a Cholesterol Genetics Heart Disease Institute Mercer University School of Pharmaceutical Sciences   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Coronary artery disease; Food and drug administration; Heart disease; Lipoproteins; Niacin; Nicotinic acid

Indexed keywords

CATECHOLAMINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ARTERIOGRAPHY; ATHEROGENESIS; BEDTIME DOSAGE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL OUTCOME; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; DRUG FORMULATION; DYSLIPIDEMIA; HEART INFARCTION PREVENTION; HORMONE RESPONSE; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASE; DOSE RESPONSE; PATHOLOGY;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; HUMANS; NIACIN; TRIGLYCERIDES;

EID: 85029480120     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2017.08.005     Document Type: Review

References (50)

1. HPS2-THRIVE Collaborative Group, Landray, M.J., Haynes, R., Hopewell, J.C., et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371 (2014), 203–212.
2. The AIM-HIGH Investigators, Boden, W.E., Probstfield, J.L., Anderson, T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365 (2011), 2255–2267.
3. FDA Federal Register. 2016. Available at: https://www.federalregister.gov/articles/2016/04/18/2016-08887/abbvie-inc-et-al-withdrawal-of-approval-of-indications-related-to-the-coadministration withstatins?utm_content=previous&utm_medium=PrevNext&utm_source=Article; Accessed April 20, 2016.
4. 2016 AHA CardioBrief: FDA Ends Niacin, Fibrate Combos With Statins and Other Coverage from AHA. Available at: http://cardiobrief.org/2016/04/17/fda-ends-niacin-and-fenofibric-acid-combinations-with-statins/. Accessed April 17, 2016.
5. Superko, H.R., Beyond LDL-C reduction. Circulation 94 (1996), 2351–2354.
6. Superko, H.R., King, S. 3rd, Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation 117 (2008), 560–568.
7. LaRosa, J.C., He, J., Vupputuri, S., Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282 (1999), 2340–2346.
8. Ridker, P.M., Danielson, E., Fonseca, F.A., et al., JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008), 2195–2207.
9. Mora, S., Caulfield, M.P., Wohlgemuth, J., et al. Atherogenic lipoprotein subfractions determined by ion mobility and first cardiovascular events after random allocation to high-intensity statin or placebo: the justification for the use of statins in prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial. Circulation 132 (2015), 2220–2229.
10. Superko, H.R., Krauss, R.M., Differential effects of niacin in subjects with different LDL subclass patterns. Atherosclerosis 95 (1992), 69–76.
11. Canner, P.L., Berge, K.G., Wenger, N.K., et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 8 (1986), 1245–1255.
12. Carlson, L.A., Niacin: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 258:2 (2005), 94–114.
13. Hotz, W., Niacin and its derivatives: a short survey. Adv Lipid Res 20 (1983), 195–217.
14. Hughes-Large, J.M., Borradaile, N.M., Gene expression microarray data from human microvascular endothelial cells supplemented with a low concentration of niacin. Data Brief 6 (2016), 899–902.
15. Superko, H.R., Lipid altering drugs LDL/HDL subclass distribution. Match the treatment to the disorder. ACC Curr J Rev 9:3 (2000), 18–24.
16. Carlson, L.A., Rosenhamer, G., Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 223 (1988), 405–418.
17. 4 S. Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. Am J Cardiol 71 (1993), 393–400.
18. Brown, G.B., Zhao, X.Q., Chait, A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:22 (2001), 1583–1592.
19. Whitney, E.J., Krasuski, R.A., Personius, B.E., et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 142 (2005), 95–104.
20. Superko, H.R., Voros, S., King, S. III, Lipoprotein metabolism and implications for atherosclerosis risk determination and treatment decisions. Shah, P.K., (eds.) Textbook on Cardiovascular Disease, 2006, Taylor & Francis Group, New York, London, 35–83.
21. Brown, G., Albers, J.J., Fisher, L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 (1990), 1289–1298.
22. Zhao, X.Q., Krasuski, R.A., Baer, J., et al. Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS). Am J Cardiol 104:11 (2009), 1457–1464.
23. Guyton, J.R., Slee, A.E., Anderson, T., et al. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). J Am Coll Cardiol 22:62 (2013), 1580–1584.
24. Zambon, A., Zhao, X.Q., Brown, B.G., Brunzell, J.D., Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease. Am J Cardiol 1:113 (2014), 1494–1498.
25. Vega, G.L., Cater, N.B., Meguro, S., Grundy, S.M., Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol 95 (2005), 1309–1313.
26. Watt, M.J., Southgate, R.J., Holmes, A.G., Febbraio, M.A., Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) alpha and delta and PPAR coactivator 1alpha in human skeletal muscle, but not lipid regulatory genes. J Mol Endocrinol 33 (2004), 533–544.
27. Lukasova, M., Malaval, C., Gille, A., Kero, J., Offermanns, S., Niacin inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest 121 (2011), 1163–1173.
28. Dunbar, R.L., Goel, H., Niacin alternatives for dyslipidemia: Fool's gold or gold mine? Part I: alternative niacin regimens. Curr Atheroslcer Rep, 18, 2016, 11.
29. Knopp, R.H., Ginsberg, J., Albers, J.J., et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 34 (1985), 642–650.
30. Goldie, C., Taylor, A.J., Nguyen, P., McCoy, C., Zhao, X.Q., Preiss, D., Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomized controlled trials. Heart 102:3 (2015), 198–203.
31. Plaisance, E.P., Lukasova, M., Offermanns, S., Zhang, Y., Cao, G., Judd, R.L., Niacin stimulates adiponectin secretion through the GPR109A receptor. Am J Physiol Endocrinol Metab 296 (2009), E549–E558.
32. Waters, D., Craven, T.E., Lesperance, J., Prognostic significance of progression of coronary atherosclerosis. Circulation 87 (1993), 1067–1075.
33. Brown, G.B., Zhao, X.Q., Sacco, D.E., Albers, J.J., Lipid lowering and plaque regression. Circulation 87 (1993), 1781–1791.
34. Blankenhorn, D.H., Nessim, S.A., Johnson, R.D., Sanmarco, M.E., Azen, S.P., Cashin-Hemphill, L., Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257 (1987), 3233–3240.
35. Kane, J.P., Malloy, M.J., Ports, T.A., Phillips, N.R., Diehl, J.C., Havel, R.J., Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264:23 (1990), 3007–3012.
36. Taylor, A.J., Lee, H.J., Sullenberger, L.E., The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 22 (2006), 2243–2250.
37. Superko, H.R., Advanced lipoprotein testing and subfractionation research tool or clinical utility?. Circulation 119 (2009), 2383–2395.
38. Yadav, R., Liu, Y., Kwok, S., et al. Effect of extended-release niacin on high-density lipoprotein (HDL) functionality, lipoprotein metabolism, and mediators of vascular inflammation in statin-treated patients. J Am Heart Assoc, 4(9), 2015, e001508.
39. Song, W.L., Stubbe, J., Ricciotti, E., Niacin and biosynthesis of PGD2 by platelet COX-1 in mice and humans. J Clin Invest 122 (2012), 1459–1468.
40. Cioni, G., Mannini, L., Liotta, A.A., et al. Detrimental effects of niacin/laropiprant on microvascular reactivity and red cell deformability in patients with elevated lipoprotein(a) levels. J Thromb Thrombolysis 41 (2016), 433–435.
41. Lavigne, P.M., Karas, R.H., The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol 61 (2013), 440–446.
42. Superko, H.R., Lakshmana, K., Pendyala, The Heart and Obesity. Rourke, R.O., Walsh, R., Fuster, V., (eds.) Hurst's The Heart Manual of Cardiology, 12th ed., 2009, The McGraw-Hill Companies, New York, NY, 618–629.
43. Wurtz, P., Wang, Q., Soininen, P., et al. Metabolomic profiling of statin use and genetic inhibition of HMG-CoA reductase. J Am Coll Cardiol 67 (2016), 1200–1213.
44. Superko, H.R., McGovern, M.E., Raul, E., Garrett, B., Niacin has a differential effect on low density lipoprotein subclass distribution in patients classified as LDL pattern A, B, or I. Am J Cardiol 94 (2004), 588–594.
45. Superko, H.R., Krauss, R.M., DiRicco, C., Effect of HMGCoA reductase inhibitor (fluvastatin) on LDL peak particle diameter. Am J Cardiol 80 (1997), 78–81.
46. Williams, P.T., Zhao, X.Q., Marcovina, S.M., Brown, B.G., Krauss, R.M., Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS). PLoS One, 8, 2013, e56782.
47. Williams, P.T., Zhao, X.Q., Marcovina, S.M., Otvos, J.D., Brown, B.G., Krauss, R.M., Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease. Atherosclerosis 233 (2014), 713–720.
48. Knopp, R.H., Alagona, P., Davidson, M., et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 47:9 (1998), 1097–1104.
49. Krauss, R.M., The tangled web of coronary risk factors. Am J Med 90 (1991), 36S–41S.
50. Johansen, C.T., Kathiresan, S., Hegele, R.A., Genetic determinants of plasma triglycerides. J Lipid Res 52:2 (2011), 189–206.